Adenosine receptors and Huntington's disease

International Review of Neurobiology

Volumn 119, Issue , 2014, Pages 195-232

  Lee, Chien fei ^a   Chern, Yijuang ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Adenosine receptor; Caffeine; GPCR; Huntington's disease; Receptor dimmer

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; PROTEASOME; CAFFEINE;

ARTICLE; ASTROCYTE; AUTOPHAGY; DISEASE COURSE; DISEASE MODEL; DRUG MECHANISM; DRUG TARGETING; EXCITOTOXICITY; GENETIC MODEL; GLIA CELL; HOMEOSTASIS; HUMAN; HUNTINGTON CHOREA; METABOLIC DISORDER; MITOCHONDRIAL DYNAMICS; NERVE CELL; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN FUNCTION; RECEPTOR OCCUPANCY; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UBIQUITINATION; ANIMAL; COMPLICATION; HUNTINGTON DISEASE; METABOLIC DISEASES; METABOLISM; MITOCHONDRIAL DISEASES;

ANIMALS; AUTOPHAGY; CAFFEINE; HUMANS; HUNTINGTON DISEASE; METABOLIC DISEASES; MITOCHONDRIAL DISEASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PURINERGIC P1 RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P1;

EID: 84906766601     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-801022-8.00010-6     Document Type: Chapter

References (163)

1. Alfinito P.D., Wang S.P., Manzino L., Rijhsinghani S., Zeevalk G.D., Sonsalla P.K. Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. The Journal of Neuroscience 2003, 23(34):10982-10987.
2. Alston T.A., Mela L., Bright H.J. 3-Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase. Proceedings of the National Academy of Sciences of the United States of America 1977, 74(9):3767-3771.
3. Atkinson B., Dwyer K., Enjyoji K., Robson S.C. Ecto-nucleotidases of the CD39/NTPDase family modulate platelet activation and thrombus formation: Potential as therapeutic targets. Blood Cells, Molecules & Diseases 2006, 36(2):217-222. 10.1016/j.bcmd.2005.12.025.
4. Bauer A., Zilles K., Matusch A., Holzmann C., Riess O., von Horsten S. Regional and subtype selective changes of neurotransmitter receptor density in a rat transgenic for the Huntington's disease mutation. Journal of Neurochemistry 2005, 94(3):639-650. 10.1111/j.1471-4159.2005.03169.x.
5. Bennett E.J., Shaler T.A., Woodman B., Ryu K.Y., Zaitseva T.S., Becker C.H., et al. Global changes to the ubiquitin system in Huntington's disease. Nature 2007, 448(7154):704-708. 10.1038/nature06022.
6. Bjorkqvist M., Wild E.J., Thiele J., Silvestroni A., Andre R., Lahiri N., et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. The Journal of Experimental Medicine 2008, 205(8):1869-1877. 10.1084/jem.20080178.
7. Blum D., Galas M.C., Pintor A., Brouillet E., Ledent C., Muller C.E., et al. A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: Implications for the neuroprotective potential of A2A antagonists. The Journal of Neuroscience 2003, 23(12):5361-5369.
8. Blum D., Gall D., Galas M.C., d'Alcantara P., Bantubungi K., Schiffmann S.N. The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. The Journal of Neuroscience 2002, 22(20):9122-9133.
9. Boison D. Adenosine kinase, epilepsy and stroke: Mechanisms and therapies. Trends in Pharmacological Sciences 2006, 27(12):652-658. 10.1016/j.tips.2006.10.008.
10. Boison D. Role of adenosine in status epilepticus: A potential new target?. Epilepsia 2013, 54(Suppl. 6):20-22. 10.1111/epi.12268.
11. Boison D., Chen J.F., Fredholm B.B. Adenosine signaling and function in glial cells. Cell Death and Differentiation 2010, 17(7):1071-1082. 10.1038/cdd.2009.131.
12. Bradford J., Shin J.Y., Roberts M., Wang C.E., Li X.J., Li S. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(52):22480-22485. 10.1073/pnas.0911503106.
13. Bradford J., Shin J.Y., Roberts M., Wang C.E., Sheng G., Li S., et al. Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. The Journal of Biological Chemistry 2010, 285(14):10653-10661. 10.1074/jbc.M109.083287.
14. Brooks D.J., Doder M., Osman S., Luthra S.K., Hirani E., Hume S., et al. Positron emission tomography analysis of [11C]KW-6002 binding to human and rat adenosine A2A receptors in the brain. Synapse 2008, 62(9):671-681. 10.1002/syn.20539.
15. Brouillet E., Jacquard C., Bizat N., Blum D. 3-Nitropropionic acid: A mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. Journal of Neurochemistry 2005, 95(6):1521-1540. 10.1111/j.1471-4159.2005.03515.x.
16. Browne S.E. Mitochondria and Huntington's disease pathogenesis: Insight from genetic and chemical models. Annals of the New York Academy of Sciences 2008, 1147:358-382. 10.1196/annals.1427.018.
17. Buira S.P., Albasanz J.L., Dentesano G., Moreno J., Martin M., Ferrer I., et al. DNA methylation regulates adenosine A(2A) receptor cell surface expression levels. Journal of Neurochemistry 2010, 112(5):1273-1285. 10.1111/j.1471-4159.2009.06538.x.
18. Buira S.P., Dentesano G., Albasanz J.L., Moreno J., Martin M., Ferrer I., et al. DNA methylation and Yin Yang-1 repress adenosine A2A receptor levels in human brain. Journal of Neurochemistry 2010, 115(1):283-295. 10.1111/j.1471-4159.2010.06928.x.
19. Bulavina L., Szulzewsky F., Rocha A., Krabbe G., Robson S.C., Matyash V., et al. NTPDase1 activity attenuates microglial phagocytosis. Purinergic Signal 2013, 9(2):199-205. 10.1007/s11302-012-9339-y.
20. Canals M., Marcellino D., Fanelli F., Ciruela F., de Benedetti P., Goldberg S.R., et al. Adenosine A2A-dopamine D2 receptor-receptor heteromerization: Qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. The Journal of Biological Chemistry 2003, 278(47):46741-46749. 10.1074/jbc.M306451200.
21. Cepeda C., Cummings D.M., Hickey M.A., Kleiman-Weiner M., Chen J.Y., Watson J.B., et al. Rescuing the corticostriatal synaptic disconnection in the R6/2 mouse model of Huntington's disease: Exercise, adenosine receptors and ampakines. PLoS Currents 2010, 2. 10.1371/currents.RRN1182.
22. Cepeda C., Wu N., Andre V.M., Cummings D.M., Levine M.S. The corticostriatal pathway in Huntington's disease. Progress in Neurobiology 2007, 81(5-6):253-271. 10.1016/j.pneurobio.2006.11.001.
23. Cha J.H., Frey A.S., Alsdorf S.A., Kerner J.A., Kosinski C.M., Mangiarini L., et al. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 1999, 354(1386):981-989.
24. Cha J.H., Kosinski C.M., Kerner J.A., Alsdorf S.A., Mangiarini L., Davies S.W., et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proceedings of the National Academy of Sciences of the United States of America 1998, 95(11):6480-6485.
25. Chan E.Y., Luthi-Carter R., Strand A., Solano S.M., Hanson S.A., DeJohn M.M., et al. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Human Molecular Genetics 2002, 11(17):1939-1951.
26. Chang D.T., Rintoul G.L., Pandipati S., Reynolds I.J. Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiology of Disease 2006, 22(2):388-400. 10.1016/j.nbd.2005.12.007.
27. Charalambous C., Gsandtner I., Keuerleber S., Milan-Lobo L., Kudlacek O., Freissmuth M., et al. Restricted collision coupling of the A2A receptor revisited: Evidence for physical separation of two signaling cascades. The Journal of Biological Chemistry 2008, 283(14):9276-9288. 10.1074/jbc.M706275200.
28. Chen J.F., Eltzschig H.K., Fredholm B.B. Adenosine receptors as drug targets-What are the challenges?. Nature Reviews. Drug Discovery 2013, 12(4):265-286. nrd3955 [pii]. 10.1038/nrd3955.
29. Chen L.L., Wu J.C., Wang L.H., Wang J., Qin Z.H., Difiglia M., et al. Rapamycin prevents the mutant huntingtin-suppressed GLT-1 expression in cultured astrocytes. Acta Pharmacologica Sinica 2012, 33(3):385-392. 10.1038/aps.2011.162.
30. Chiang M.C., Chen H.M., Lai H.L., Chen H.W., Chou S.Y., Chen C.M., et al. The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system. Human Molecular Genetics 2009, 18(16):2929-2942. 10.1093/hmg/ddp230.
31. Chiang M.C., Lee Y.C., Huang C.L., Chern Y. cAMP-response element-binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues. The Journal of Biological Chemistry 2005, 280(14):14331-14340. 10.1074/jbc.M413279200.
32. Chiu E., Mackay I.R., Bhathal P.B. Hepatic morphology in Huntington's chorea. Journal of Neurology, Neurosurgery, and Psychiatry 1975, 38(10):1000-1002.
33. Chou S.Y., Lee Y.C., Chen H.M., Chiang M.C., Lai H.L., Chang H.H., et al. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. Journal of Neurochemistry 2005, 93(2):310-320. 10.1111/j.1471-4159.2005.03029.x.
34. Chou S.Y., Weng J.Y., Lai H.L., Liao F., Sun S.H., Tu P.H., et al. Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes. The Journal of Neuroscience 2008, 28(13):3277-3290. 10.1523/JNEUROSCI.0116-08.2008.
35. Ciarmiello A., Giovacchini G., Orobello S., Bruselli L., Elifani F., Squitieri F. 18F-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size. European Journal of Nuclear Medicine and Molecular Imaging 2012, 39(6):1030-1036. 10.1007/s00259-012-2114-z.
36. Cipriani S., Bizzoco E., Gianfriddo M., Melani A., Vannucchi M.G., Pedata F. Adenosine A2A receptor antagonism increases nNOS-immunoreactive neurons in the striatum of Huntington transgenic mice. Experimental Neurology 2008, 213(1):163-170. 10.1016/j.expneurol.2008.05.015.
37. Ciruela F., Ferre S., Casado V., Cortes A., Cunha R.A., Lluis C., et al. Heterodimeric adenosine receptors: A device to regulate neurotransmitter release. Cellular and Molecular Life Sciences 2006, 63(21):2427-2431. 10.1007/s00018-006-6216-2.
38. Cloud L.J., Rosenblatt A., Margolis R.L., Ross C.A., Pillai J.A., Corey-Bloom J., et al. Seizures in juvenile Huntington's disease: Frequency and characterization in a multicenter cohort. Movement Disorders 2012, 27(14):1797-1800. 10.1002/mds.25237.
39. Cornelis M.C., El-Sohemy A., Campos H. Genetic polymorphism of the adenosine A2A receptor is associated with habitual caffeine consumption. The American Journal of Clinical Nutrition 2007, 86(1):240-244.
40. Costa V., Giacomello M., Hudec R., Lopreiato R., Ermak G., Lim D., et al. Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli. EMBO Molecular Medicine 2010, 2(12):490-503. 10.1002/emmm.201000102.
41. Crotti A., Benner C., Kerman B.E., Gosselin D., Lagier-Tourenne C., Zuccato C., et al. Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nature Neuroscience 2014, 10.1038/nn.3668.
42. del Toro D., Xifro X., Pol A., Humbert S., Saudou F., Canals J.M., et al. Altered cholesterol homeostasis contributes to enhanced excitotoxicity in Huntington's disease. Journal of Neurochemistry 2010, 115(1):153-167. 10.1111/j.1471-4159.2010.06912.x.
43. Dhaenens C.M., Burnouf S., Simonin C., Van Brussel E., Duhamel A., Defebvre L., et al. A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease. Neurobiology of Disease 2009, 35(3):474-476. 10.1016/j.nbd.2009.06.009.
44. DiFiglia M. Excitotoxic injury of the neostriatum: A model for Huntington's disease. Trends in Neurosciences 1990, 13(7):286-289.
45. Diogenes M.J., Fernandes C.C., Sebastiao A.M., Ribeiro J.A. Activation of adenosine A2A receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices. The Journal of Neuroscience 2004, 24(12):2905-2913. 10.1523/JNEUROSCI.4454-03.2004.
46. Diogenes M.J., Neves-Tome R., Fucile S., Martinello K., Scianni M., Theofilas P., et al. Homeostatic control of synaptic activity by endogenous adenosine is mediated by adenosine kinase. Cerebral Cortex 2014, 24(1):67-80. 10.1093/cercor/bhs284.
47. Domenici M.R., Scattoni M.L., Martire A., Lastoria G., Potenza R.L., Borioni A., et al. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice. Neurobiology of Disease 2007, 28(2):197-205. 10.1016/j.nbd.2007.07.009.
48. Eltzschig H.K., Eckle T., Mager A., Kuper N., Karcher C., Weissmuller T., et al. ATP release from activated neutrophils occurs via connexin 43 and modulates adenosine-dependent endothelial cell function. Circulation Research 2006, 99(10):1100-1108. 10.1161/01.RES.0000250174.31269.70.
49. Fan J., Cowan C.M., Zhang L.Y., Hayden M.R., Raymond L.A. Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease. The Journal of Neuroscience 2009, 29(35):10928-10938. 10.1523/JNEUROSCI.2491-09.2009.
50. Fan M.M., Raymond L.A. N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Progress in Neurobiology 2007, 81(5-6):272-293. 10.1016/j.pneurobio.2006.11.003.
51. Farber K., Markworth S., Pannasch U., Nolte C., Prinz V., Kronenberg G., et al. The ectonucleotidase cd39/ENTPDase1 modulates purinergic-mediated microglial migration. Glia 2008, 56(3):331-341. 10.1002/glia.20606.
52. Feigin A., Tang C., Ma Y., Mattis P., Zgaljardic D., Guttman M., et al. Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain 2007, 130(Pt 11):2858-2867. 10.1093/brain/awm217.
53. Ferrante A., Martire A., Armida M., Chiodi V., Pezzola A., Potenza R.L., et al. Influence of CGS 21680, a selective adenosine A(2A) receptor agonist, on NMDA receptor function and expression in the brain of Huntington's disease mice. Brain Research 2010, 1323:184-191. 10.1016/j.brainres.2010.01.080.
54. Ferre S., Casado V., Devi L.A., Filizola M., Jockers R., Lohse M.J., et al. G protein-coupled receptor oligomerization revisited: Functional and pharmacological perspectives. Pharmacological Reviews 2014, 66(2):413-434. 10.1124/pr.113.008052.
55. Ferre S., Goldberg S.R., Lluis C., Franco R. Looking for the role of cannabinoid receptor heteromers in striatal function. Neuropharmacology 2009, 56(Suppl 1):226-234. S0028-3908(08)00265-7 [pii]. 10.1016/j.neuropharm.2008.06.076.
56. Fink J.S., Kalda A., Ryu H., Stack E.C., Schwarzschild M.A., Chen J.F., et al. Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage. Journal of Neurochemistry 2004, 88(3):538-544.
57. Fontinha B.M., Diogenes M.J., Ribeiro J.A., Sebastiao A.M. Enhancement of long-term potentiation by brain-derived neurotrophic factor requires adenosine A2A receptor activation by endogenous adenosine. Neuropharmacology 2008, 54(6):924-933. 10.1016/j.neuropharm.2008.01.011.
58. Fredholm B.B. Adenosine and metabolism-A brief historical note. Adenosine: A key link between metabolism and brain activity 2013, 3-22. Springer, New York. 10.1007/978-1-4614-3903-5. S. Masino, D. Boison (Eds.).
59. Galluzzo M., Pintor A., Pezzola A., Grieco R., Borsini F., Popoli P. Behavioural and neurochemical characterization of the adenosine A2A receptor antagonist ST1535. European Journal of Pharmacology 2008, 579(1-3):149-152. 10.1016/j.ejphar.2007.10.057.
60. Gauthier L.R., Charrin B.C., Borrell-Pages M., Dompierre J.P., Rangone H., Cordelieres F.P., et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004, 118(1):127-138. 10.1016/j.cell.2004.06.018.
61. Georgiou-Karistianis N., Scahill R., Tabrizi S.J., Squitieri F., Aylward E. Structural MRI in Huntington's disease and recommendations for its potential use in clinical trials. Neuroscience and Biobehavioral Reviews 2013, 37(3):480-490. S0149-7634(13)00029-8 [pii]. 10.1016/j.neubiorev.2013.01.022.
62. Gharami K., Xie Y., An J.J., Tonegawa S., Xu B. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice. Journal of Neurochemistry 2008, 105(2):369-379. 10.1111/j.1471-4159.2007.05137.x.
63. Giampa C., Laurenti D., Anzilotti S., Bernardi G., Menniti F.S., Fusco F.R. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS One 2010, 5(10):e13417. 10.1371/journal.pone.0013417.
64. Gianfriddo M., Melani A., Turchi D., Giovannini M.G., Pedata F. Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow. Neurobiology of Disease 2004, 17(1):77-88. 10.1016/j.nbd.2004.05.008.
65. Glass M., Dragunow M., Faull R.L. The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABA(a) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000, 97(3):505-519.
66. Graham R.K., Pouladi M.A., Joshi P., Lu G., Deng Y., Wu N.P., et al. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. The Journal of Neuroscience 2009, 29(7):2193-2204. 29/7/2193 [pii]. 10.1523/JNEUROSCI.5473-08.2009.
67. Guo X., Disatnik M.H., Monbureau M., Shamloo M., Mochly-Rosen D., Qi X. Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration. The Journal of Clinical Investigation 2013, 123(12):5371-5388. 10.1172/JCI70911.
68. Hsiao H.Y., Chen Y.C., Chen H.M., Tu P.H., Chern Y. A critical role of astrocyte-mediated nuclear factor-kappaB-dependent inflammation in Huntington's disease. Human Molecular Genetics 2013, 22(9):1826-1842. 10.1093/hmg/ddt036.
69. Hsiao H.Y., Chern Y. Targeting glial cells to elucidate the pathogenesis of Huntington's disease. Molecular Neurobiology 2010, 41(2-3):248-255. 10.1007/s12035-009-8097-5.
70. Hsiao H.Y., Chiu F.L., Chen C.M., Wu Y.R., Chen H.M., Chen Y.C., et al. Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease. Human Molecular Genetics 2014, ddu151 [pii]. 10.1093/hmg/ddu151.
71. Huang N.K., Lin J.H., Lin J.T., Lin C.I., Liu E.M., Lin C.J., et al. A new drug design targeting the adenosinergic system for Huntington's disease. PLoS One 2011, 6(6):e20934. 10.1371/journal.pone.0020934.
72. Huang Q.Y., Wei C., Yu L., Coelho J.E., Shen H.Y., Kalda A., et al. Adenosine A2A receptors in bone marrow-derived cells but not in forebrain neurons are important contributors to 3-nitropropionic acid-induced striatal damage as revealed by cell-type-selective inactivation. The Journal of Neuroscience 2006, 26(44):11371-11378. 10.1523/JNEUROSCI.1907-06.2006.
73. Huang C.L., Yang J.M., Wang K.C., Lee Y.C., Lin Y.L., Yang Y.C., et al. Gastrodia elata prevents huntingtin aggregations through activation of the adenosine A(2) A receptor and ubiquitin proteasome system. Journal of Ethnopharmacology 2011, 138(1):162-168. 10.1016/j.jep.2011.08.075.
74. Huang Q., Zhou D., Sapp E., Aizawa H., Ge P., Bird E.D., et al. Quinolinic acid-induced increases in calbindin D28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease. Neuroscience 1995, 65(2):397-407.
75. Ishiwata K., Kimura Y., Vries De, Erik F.J., Elsinga P.H. PET tracers for mapping adenosine receptors as probes for diagnosis of CNS disorders. Central Nervous System Agents in Medicinal Chemistry 2007, 7(1):57-77.
76. Ishiwata K., Ogi N., Hayakawa N., Oda K., Nagaoka T., Toyama H., et al. Adenosine A2A receptor imaging with [11C]KF18446 PET in the rat brain after quinolinic acid lesion: Comparison with the dopamine receptor imaging. Annals of Nuclear Medicine 2002, 16(7):467-475.
77. Jacobson K.A., Balasubramanian R., Deflorian F., Gao Z.G. G protein-coupled adenosine (P1) and P2Y receptors: Ligand design and receptor interactions. Purinergic Signal 2012, 8(3):419-436. 10.1007/s11302-012-9294-7.
78. Jia H., Kast R.J., Steffan J.S., Thomas E.A. Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: Implications for the ubiquitin-proteasomal and autophagy systems. Human Molecular Genetics 2012, 21(24):5280-5293. 10.1093/hmg/dds379.
79. Jiang M., Peng Q., Liu X., Jin J., Hou Z., Zhang J., et al. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease. Human Molecular Genetics 2013, 22(12):2462-2470. 10.1093/hmg/ddt098.
80. Ju T.C., Chen H.M., Lin J.T., Chang C.P., Chang W.C., Kang J.J., et al. Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntington's disease. The Journal of Cell Biology 2011, 194(2):209-227. 10.1083/jcb.201105010.
81. Khanapur S., Waarde Av, Ishiwata K., Leenders K.L., Dierckx R.A., Elsinga P.H. Adenosine A(2A) receptor antagonists as positron emission tomography (PET) tracers. Current Medicinal Chemistry 2013, 21(3):312-328.
82. Kim W., Seo H. Baclofen, a GABAB receptor agonist, enhances ubiquitin-proteasome system functioning and neuronal survival in Huntington's disease model mice. Biochemical and Biophysical Research Communications 2014, 443(2):706-711. 10.1016/j.bbrc.2013.12.034.
83. Koga H., Martinez-Vicente M., Arias E., Kaushik S., Sulzer D., Cuervo A.M. Constitutive upregulation of chaperone-mediated autophagy in Huntington's disease. The Journal of Neuroscience 2011, 31(50):18492-18505. 10.1523/JNEUROSCI.3219-11.2011.
84. Kulesskaya N., Voikar V., Peltola M., Yegutkin G.G., Salmi M., Jalkanen S., et al. CD73 is a major regulator of adenosinergic signalling in mouse brain. PLoS One 2013, 8(6):e66896. 10.1371/journal.pone.0066896.
85. Labbadia J., Morimoto R.I. Huntington's disease: Underlying molecular mechanisms and emerging concepts. Trends in Biochemical Sciences 2013, 38(8):378-385. S0968-0004(13)00078-9 [pii]. 10.1016/j.tibs.2013.05.003.
86. Lee C.Y., Cantle J.P., Yang X.W. Genetic manipulations of mutant huntingtin in mice: New insights into Huntington's disease pathogenesis. The FEBS Journal 2013, 280(18):4382-4394. 10.1111/febs.12418.
87. Lee F.S., Chao M.V. Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(6):3555-3560. 10.1073/pnas.061020198.
88. Lee Y.C., Lai H.L., Sun C.N., Chien C.L., Chern Y. Identification of nuclear factor 1 (NF1) as a transcriptional modulator of rat A(2A) adenosine receptor. Brain Research. Molecular Brain Research 2003, 111(1-2):61-73.
89. Lee W., Reyes R.C., Gottipati M.K., Lewis K., Lesort M., Parpura V., et al. Enhanced Ca(2+)-dependent glutamate release from astrocytes of the BACHD Huntington's disease mouse model. Neurobiology of Disease 2013, 58:192-199. 10.1016/j.nbd.2013.06.002.
90. Li B., Gu L., Hertz L., Peng L. Expression of nucleoside transporter in freshly isolated neurons and astrocytes from mouse brain. Neurochemical Research 2013, 38(11):2351-2358. 10.1007/s11064-013-1146-5.
91. Li T., Quan Lan J., Fredholm B.B., Simon R.P., Boison D. Adenosine dysfunction in astrogliosis: Cause for seizure generation?. Neuron Glia Biology 2007, 3(4):353-366. 10.1017/S1740925X0800015X.
92. Lin J.T., Chang W.C., Chen H.M., Lai H.L., Chen C.Y., Tao M.H., et al. Regulation of feedback between protein kinase A and the proteasome system worsens Huntington's disease. Molecular and Cellular Biology 2013, 33(5):1073-1084. 10.1128/MCB.01434-12.
93. Lin Y.S., Cheng T.H., Chang C.P., Chen H.M., Chern Y. Enhancement of brain-type creatine kinase activity ameliorates neuronal deficits in Huntington's disease. Biochimica et Biophysica Acta 2013, 1832(6):742-753. 10.1016/j.bbadis.2013.02.006.
94. Liu Y., Hettinger C.L., Zhang D., Rezvani K., Wang X., Wang H. Sulforaphane enhances proteasomal and autophagic activities in mice and is a potential therapeutic reagent for Huntington's disease. Journal of Neurochemistry 2014, 10.1111/jnc.12647.
95. Luthi-Carter R., Strand A., Peters N.L., Solano S.M., Hollingsworth Z.R., Menon A.S., et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Human Molecular Genetics 2000, 9(9):1259-1271.
96. Maglione V., Cannella M., Martino T., De Blasi A., Frati L., Squitieri F. The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington's disease patients with predominant chorea. Neuroscience Letters 2006, 393(1):27-30. 10.1016/j.neulet.2005.09.037.
97. Maglione V., Giallonardo P., Cannella M., Martino T., Frati L., Squitieri F. Adenosine A2A receptor dysfunction correlates with age at onset anticipation in blood platelets of subjects with Huntington's disease. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2005, 139B(1):101-105. 10.1002/ajmg.b.30223.
98. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87(3):493-506.
99. Marco S., Giralt A., Petrovic M.M., Pouladi M.A., Martinez-Turrillas R., Martinez-Hernandez J., et al. Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models. Nature Medicine 2013, 19(8):1030-1038. 10.1038/nm.3246.
100. Martinez-Mir M.I., Probst A., Palacios J.M. Adenosine A2 receptors: Selective localization in the human basal ganglia and alterations with disease. Neuroscience 1991, 42(3):697-706.
101. Martinez-Vicente M., Talloczy Z., Wong E., Tang G., Koga H., Kaushik S., et al. Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. Nature Neuroscience 2010, 13(5):567-576. 10.1038/nn.2528.
102. Martire A., Calamandrei G., Felici F., Scattoni M.L., Lastoria G., Domenici M.R., et al. Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice. Neuroscience Letters 2007, 417(1):78-83. 10.1016/j.neulet.2007.02.034.
103. Martire A., Ferrante A., Potenza R.L., Armida M., Ferretti R., Pezzola A., et al. Remodeling of striatal NMDA receptors by chronic A(2A) receptor blockade in Huntington's disease mice. Neurobiology of Disease 2010, 37(1):99-105. 10.1016/j.nbd.2009.09.012.
104. Martire A., Pepponi R., Domenici M.R., Ferrante A., Chiodi V., Popoli P. BDNF prevents NMDA-induced toxicity in models of Huntington's disease: The effects are genotype specific and adenosine A(2A) receptor is involved. Journal of Neurochemistry 2013, 10.1111/jnc.12177.
105. Matusch A., Saft C., Elmenhorst D., Kraus P.H., Gold R., Hartung H.P., et al. Cross sectional PET study of cerebral adenosine A receptors in premanifest and manifest Huntington's disease. European Journal of Nuclear Medicine and Molecular Imaging 2014, 10.1007/s00259-014-2724-8.
106. Messam C.A., Greene J.G., Greenamyre J.T., Robinson M.B. Intrastriatal injections of the succinate dehydrogenase inhibitor, malonate, cause a rise in extracellular amino acids that is blocked by MK-801. Brain Research 1995, 684(2):221-224.
107. Mievis S., Blum D., Ledent C. A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease. Neurobiology of Disease 2011, 41(2):570-576. 10.1016/j.nbd.2010.09.021.
108. Mishina M., Ishiwata K., Kimura Y., Naganawa M., Oda K., Kobayashi S., et al. Evaluation of distribution of adenosine A2A receptors in normal human brain measured with [11C]TMSX PET. Synapse 2007, 61(9):778-784. 10.1002/syn.20423.
109. Mishina M., Kimura Y., Naganawa M., Ishii K., Oda K., Sakata M., et al. Differential effects of age on human striatal adenosine A(1) and A(2A) receptors. Synapse 2012, 66(9):832-839. 10.1002/syn.21573.
110. Naganawa M., Kimura Y., Mishina M., Manabe Y., Chihara K., Oda K., et al. Quantification of adenosine A2A receptors in the human brain using [11C]TMSX and positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging 2007, 34(5):679-687. 10.1007/s00259-006-0294-0.
111. Orru M., Zanoveli J.M., Quiroz C., Nguyen H.P., Guitart X., Ferre S. Functional changes in postsynaptic adenosine A(2A) receptors during early stages of a rat model of Huntington disease. Experimental Neurology 2011, 232(1):76-80. 10.1016/j.expneurol.2011.08.005.
112. Panov A.V., Gutekunst C.A., Leavitt B.R., Hayden M.R., Burke J.R., Strittmatter W.J., et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nature Neuroscience 2002, 5(8):731-736. 10.1038/nn884.
113. Popoli P., Blum D., Domenici M.R., Burnouf S., Chern Y. A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's disease. Current Pharmaceutical Design 2008, 14(15):1500-1511.
114. Popoli P., Pezzola A., Reggio R., Caporali M.G., Scotti de Carolis A. CGS 21680 antagonizes motor hyperactivity in a rat model of Huntington's disease. European Journal of Pharmacology 1994, 257(1-2):R5-6.
115. Popoli P., Pintor A., Domenici M.R., Frank C., Tebano M.T., Pezzola A., et al. Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: Possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. The Journal of Neuroscience 2002, 22(5):1967-1975.
116. Potenza R.L., Tebano M.T., Martire A., Domenici M.R., Pepponi R., Armida M., et al. Adenosine A(2A) receptors modulate BDNF both in normal conditions and in experimental models of Huntington's disease. Purinergic Signal 2007, 3(4):333-338. 10.1007/s11302-007-9066-y.
117. Pouladi M.A., Morton A.J., Hayden M.R. Choosing an animal model for the study of Huntington's disease. Nature Reviews. Neuroscience 2013, 14(10):708-721. nrn3570 [pii]. 10.1038/nrn3570.
118. Powers W.J., Videen T.O., Markham J., McGee-Minnich L., Antenor-Dorsey J.V., Hershey T., et al. Selective defect of in vivo glycolysis in early Huntington's disease striatum. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(8):2945-2949. 10.1073/pnas.0609833104.
119. Reggio R., Pezzola A., Popoli P. The intrastriatal injection of an adenosine A(2) receptor antagonist prevents frontal cortex EEG abnormalities in a rat model of Huntington's disease. Brain Research 1999, 831(1-2):315-318.
120. Reilmann R. Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline. Movement Disorders 2013, 28(8):1030-1033. 10.1002/mds.25500.
121. Rogers P.J., Hohoff C., Heatherley S.V., Mullings E.L., Maxfield P.J., Evershed R.P., et al. Association of the anxiogenic and alerting effects of caffeine with ADORA2A and ADORA1 polymorphisms and habitual level of caffeine consumption. Neuropsychopharmacology 2010, 35(9):1973-1983. 10.1038/npp.2010.71.
122. Sarkar S., Perlstein E.O., Imarisio S., Pineau S., Cordenier A., Maglathlin R.L., et al. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nature Chemical Biology 2007, 3(6):331-338. 10.1038/nchembio883.
123. Scattoni M.L., Valanzano A., Pezzola A., March Z.D., Fusco F.R., Popoli P., et al. Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease. Behavioural Brain Research 2007, 176(2):216-221. 10.1016/j.bbr.2006.10.004.
124. Seo H., Sonntag K.C., Isacson O. Generalized brain and skin proteasome inhibition in Huntington's disease. Annals of Neurology 2004, 56(3):319-328. 10.1002/ana.20207.
125. Seo H., Sonntag K.C., Kim W., Cattaneo E., Isacson O. Proteasome activator enhances survival of Huntington's disease neuronal model cells. PLoS One 2007, 2(2):e238. 10.1371/journal.pone.0000238.
126. Shin J.Y., Fang Z.H., Yu Z.X., Wang C.E., Li S.H., Li X.J. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. The Journal of Cell Biology 2005, 171(6):1001-1012. 10.1083/jcb.200508072.
127. Simonin C., Duru C., Salleron J., Hincker P., Charles P., Delval A., et al. Association between caffeine intake and age at onset in Huntington's disease. Neurobiology of Disease 2013, 58:179-182. 10.1016/j.nbd.2013.05.013.
128. Song W., Chen J., Petrilli A., Liot G., Klinglmayr E., Zhou Y., et al. Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nature Medicine 2011, 17(3):377-382. 10.1038/nm.2313.
129. Svenningsson P., Hall H., Sedvall G., Fredholm B.B. Distribution of adenosine receptors in the postmortem human brain: An extended autoradiographic study. Synapse 1997, 27(4):322-335. 10.1002/(SICI)1098-2396(199712)27:4<322::AID-SYN6>3.0.CO;2-E [pii]. 10.1002/(SICI)1098-2396(199712)27:4<322::AID-SYN6>3.0.CO;2-E.
130. Tabrizi S.J., Scahill R.I., Owen G., Durr A., Leavitt B.R., Roos R.A., et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: Analysis of 36-month observational data. Lancet Neurology 2013, 12(7):637-649. 10.1016/S1474-4422(13)70088-7.
131. Taherzadeh-Fard E., Saft C., Wieczorek S., Epplen J.T., Arning L. Age at onset in Huntington's disease: Replication study on the associations of ADORA2A, HAP1 and OGG1. Neurogenetics 2010, 11(4):435-439. 10.1007/s10048-010-0248-3.
132. Tarditi A., Camurri A., Varani K., Borea P.A., Woodman B., Bates G., et al. Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease. Neurobiology of Disease 2006, 23(1):44-53. 10.1016/j.nbd.2006.01.014.
133. Taylor-Robinson S.D., Weeks R.A., Bryant D.J., Sargentoni J., Marcus C.D., Harding A.E., et al. Proton magnetic resonance spectroscopy in Huntington's disease: Evidence in favour of the glutamate excitotoxic theory. Movement Disorders 1996, 11(2):167-173. 10.1002/mds.870110209.
134. Taylor-Robinson S.D., Weeks R.A., Sargentoni J., Marcus C.D., Bryant D.J., Harding A.E., et al. Evidence for glutamate excitotoxicity in Huntington's disease with proton magnetic resonance spectroscopy. Lancet 1994, 343(8906):1170.
135. Tebano M.T., Pintor A., Frank C., Domenici M.R., Martire A., Pepponi R., et al. Adenosine A2A receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum. Journal of Neuroscience Research 2004, 77(1):100-107. 10.1002/jnr.20138.
136. Thurner P., Gsandtner I., Kudlacek O., Choquet D., Nanoff C., Freissmuth M., et al. A Two-state model for the diffusion of the A2A adenosine receptor in hippocampal neurons: Agonist-induced switch to slow mobility is modified by synapse-associated protein 102 (SAP102). The Journal of Biological Chemistry 2014, 289(13):9263-9274. 10.1074/jbc.M113.505685.
137. Todd D., Gowers I., Dowler S.J., Wall M.D., McAllister G., Fischer D.F., et al. A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington's disease. PLoS One 2014, 9(2):e87923. 10.1371/journal.pone.0087923.
138. Trincavelli M.L., Daniele S., Orlandini E., Navarro G., Casado V., Giacomelli C., et al. A new D(2) dopamine receptor agonist allosterically modulates A(2A) adenosine receptor signalling by interacting with the A(2A)/D(2) receptor heteromer. Cellular Signalling 2012, 24(4):951-960. S0898-6568(11)00410-4 [pii]. 10.1016/j.cellsig.2011.12.018.
139. Valenza M., Carroll J.B., Leoni V., Bertram L.N., Bjorkhem I., Singaraja R.R., et al. Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Human Molecular Genetics 2007, 16(18):2187-2198. 10.1093/hmg/ddm170.
140. Valenza M., Leoni V., Tarditi A., Mariotti C., Bjorkhem I., Di Donato S., et al. Progressive dysfunction of the cholesterol biosynthesis pathway in the R6/2 mouse model of Huntington's disease. Neurobiology of Disease 2007, 28(1):133-142. 10.1016/j.nbd.2007.07.004.
141. Valenza M., Rigamonti D., Goffredo D., Zuccato C., Fenu S., Jamot L., et al. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. The Journal of Neuroscience 2005, 25(43):9932-9939. 10.1523/JNEUROSCI.3355-05.2005.
142. Varani K., Bachoud-Levi A.C., Mariotti C., Tarditi A., Abbracchio M.P., Gasperi V., et al. Biological abnormalities of peripheral A(2A) receptors in a large representation of polyglutamine disorders and Huntington's disease stages. Neurobiology of Disease 2007, 27(1):36-43. 10.1016/j.nbd.2007.03.011.
143. Varani K., Rigamonti D., Sipione S., Camurri A., Borea P.A., Cattabeni F., et al. Aberrant amplification of A(2A) receptor signaling in striatal cells expressing mutant huntingtin. The FASEB Journal 2001, 15(7):1245-1247.
144. Villar-Menendez I., Blanch M., Tyebji S., Pereira-Veiga T., Albasanz J.L., Martin M., et al. Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease. Neuromolecular Medicine 2013, 15(2):295-309. 10.1007/s12017-013-8219-0.
145. Wall M.J., Dale N. Neuronal transporter and astrocytic ATP exocytosis underlie activity-dependent adenosine release in the hippocampus. The Journal of Physiology 2013, 591(Pt 16):3853-3871. 10.1113/jphysiol.2013.253450.
146. Wang L., Lin F., Wang J., Wu J., Han R., Zhu L., et al. Expression of mutant N-terminal huntingtin fragment (htt552-100Q) in astrocytes suppresses the secretion of BDNF. Brain Research 2012, 1449:69-82. 10.1016/j.brainres.2012.01.077.
147. Wang J., Wang C.E., Orr A., Tydlacka S., Li S.H., Li X.J. Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice. The Journal of Cell Biology 2008, 180(6):1177-1189. 10.1083/jcb.200709080.
148. Weiss A., Trager U., Wild E.J., Grueninger S., Farmer R., Landles C., et al. Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. The Journal of Clinical Investigation 2012, 122(10):3731-3736. 10.1172/JCI64565.
149. Whitehouse P.J., Trifiletti R.R., Jones B.E., Folstein S., Price D.L., Snyder S.H., et al. Neurotransmitter receptor alterations in Huntington's disease: Autoradiographic and homogenate studies with special reference to benzodiazepine receptor complexes. Annals of Neurology 1985, 18(2):202-210. 10.1002/ana.410180207.
150. Wiese S., Jablonka S., Holtmann B., Orel N., Rajagopal R., Chao M.V., et al. Adenosine receptor A2A-R contributes to motoneuron survival by transactivating the tyrosine kinase receptor TrkB. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(43):17210-17215. 10.1073/pnas.0705267104.
151. Williams A., Sarkar S., Cuddon P., Ttofi E.K., Saiki S., Siddiqi F.H., et al. Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nature Chemical Biology 2008, 4(5):295-305. 10.1038/nchembio.79.
152. Williams-Karnesky R.L., Sandau U.S., Lusardi T.A., Lytle N.K., Farrell J.M., Pritchard E.M., et al. Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis. The Journal of Clinical Investigation 2013, 123(8):3552-3563. 10.1172/JCI65636.
153. Wink M.R., Braganhol E., Tamajusuku A.S., Lenz G., Zerbini L.F., Libermann T.A., et al. Nucleoside triphosphate diphosphohydrolase-2 (NTPDase2/CD39L1) is the dominant ectonucleotidase expressed by rat astrocytes. Neuroscience 2006, 138(2):421-432. 10.1016/j.neuroscience.2005.11.039.
154. Wojtowicz A.M., Dvorzhak A., Semtner M., Grantyn R. Reduced tonic inhibition in striatal output neurons from Huntington mice due to loss of astrocytic GABA release through GAT-3. Frontiers in Neural Circuits 2013, 7:188. 10.3389/fncir.2013.00188.
155. Wong H.K., Bauer P.O., Kurosawa M., Goswami A., Washizu C., Machida Y., et al. Blocking acid-sensing ion channel 1 alleviates Huntington's disease pathology via an ubiquitin-proteasome system-dependent mechanism. Human Molecular Genetics 2008, 17(20):3223-3235. 10.1093/hmg/ddn218.
156. Xie Y., Hayden M.R., Xu B. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. The Journal of Neuroscience 2010, 30(44):14708-14718. 10.1523/JNEUROSCI.1637-10.2010.
157. Yegutkin G.G. Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. Biochimica et Biophysica Acta 2008, 1783(5):673-694. 10.1016/j.bbamcr.2008.01.024.
158. Young J.D., Yao S.Y., Baldwin J.M., Cass C.E., Baldwin S.A. The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. Molecular Aspects of Medicine 2013, 34(2-3):529-547. 10.1016/j.mam.2012.05.007.
159. Zuccato C., Belyaev N., Conforti P., Ooi L., Tartari M., Papadimou E., et al. Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease. The Journal of Neuroscience 2007, 27(26):6972-6983. 10.1523/JNEUROSCI.4278-06.2007.
160. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293(5529):493-498. 10.1126/science.1059581.
161. Zuccato C., Marullo M., Conforti P., MacDonald M.E., Tartari M., Cattaneo E. Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathology 2008, 18(2):225-238. 10.1111/j.1750-3639.2007.00111.x.
162. Zuccato C., Tartari M., Crotti A., Goffredo D., Valenza M., Conti L., et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nature Genetics 2003, 35(1):76-83. 10.1038/ng1219.
163. Zuchora B., Turski W.A., Wielosz M., Urbanska E.M. Protective effect of adenosine receptor agonists in a new model of epilepsy-seizures evoked by mitochondrial toxin, 3-nitropropionic acid, in mice. Neuroscience Letters 2001, 305(2):91-94.